US drug ‘gatekeepers’ face FTC antitrust lawsuit over insulin costs

Unlock the Editor’s Digest totally free

Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly e-newsletter.

The Federal Commerce Fee has sued America’s largest prescription-drug “gatekeepers” over a “perverse drug rebate system” that it alleges artificially raised insulin costs.

The competitors regulator’s criticism names CVS Well being’s Caremark, Cigna’s Categorical Scripts and UnitedHealth Group’s Optum, which administer about 80 per cent of all prescriptions within the US and generate greater than $400bn in mixed annual revenues.

The FTC, led by chair Lina Khan, is in search of to finally decrease insurance coverage premiums in addition to wholesale costs, which within the case of Humalog, an Eli Lilly insulin drug, ballooned greater than 1,200 per cent between 1999 and 2017, to greater than $274, based on the company.

Rahul Rao, deputy director of the FTC’s competitors bureau, mentioned: “Caremark, ESI and Optum — as remedy gatekeepers — have extracted hundreds of thousands of {dollars} off the backs of sufferers who want life-saving drugs.”

Pharmacy profit managers, or PBMs, act as middlemen throughout the pharmaceutical business. They negotiate rebates from wholesale costs with drugmakers, earlier than passing a few of the low cost on to shoppers and pocketing the remaining as income.

Following sweeping consolidation within the aftermath of the Inexpensive Care Act, the largest PBMs at the moment are owned by massive insurers. Drugmakers have blamed PBMs for inflating drug costs, whereas unbiased pharmacies have mentioned they offer preferential therapy to the pharmacy chains they personal.

The FTC alleges the three PBMs routinely favoured higher-priced insulin that might lead to greater rebates and costs for themselves.

Rao mentioned the criticism, which has not but been made public, “seeks to place an finish to the massive three PBMs’ exploitative conduct and marks an necessary step in fixing a damaged system — a repair that would ripple past the insulin market and restore wholesome competitors to drive down drug costs for shoppers”.

CVS mentioned the FTC’s accusations had been “merely flawed”. Andrea Nelson, Cigna’s chief authorized officer, mentioned the lawsuit “continues a troubling sample from the FTC of unsubstantiated and ideologically-driven assaults on pharmacy profit managers”.

UnitedHealth didn’t instantly reply to a request for remark.

The FTC mentioned it was additionally troubled by the function performed by drug producers reminiscent of Eli Lilly, Novo Nordisk, and Sanofi within the value system for insulin. PBMs “usually are not the one doubtlessly culpable actors”, the company mentioned.

Khan has lengthy targeted on what she has described as PBMs’ outsized energy within the US healthcare system, arguing it has harmed market competitors in addition to shoppers.

The transfer comes simply days after Categorical Scripts sued the FTC over a examine the company revealed in July, which argued PBMs inflated drug costs on the expense of pharmacies and sufferers. The corporate is demanding retractions. The FTC mentioned it stood by its report.